Joe C. Pillman

Retired Partner

Joe Pillman is a retired partner who built a substantial practice working with local, national and international companies on a variety of corporate matters. His practice concentrated on venture capital, corporate finance, mergers and acquisitions and international law. With his extensive experience and knowledge of a wide range of transactions, Mr. Pillman successfully represented a variety of clients, and had a particular reputation for representing those in the life sciences and technology sectors.

Mr. Pillman focused on securities law, including public and private securities offerings, mergers and acquisitions, as well as a range of international matters, including public and private placements for overseas issuers, and inward and outward bound acquisition transactions. He also has extensive experience with management and leveraged buy-outs, venture capital transactions and other private fund raising issues.

Mr. Pillman's clients included companies engaged in a wide range of technology sectors such as life sciences, telecommunications equipment, networking systems, Internet infrastructure, semiconductor design and manufacture, and advanced software systems and applications products.

Experience

Recent Highlights

  • MBO of PowderMed from Chiron
  • Sale of Domantis to GSK
  • Sale of Avidex to MediGene

Recognition

  • Regularly named as a leading corporate practitioner in Chambers Guide to the Legal Profession.
  • Recommended in the 2008–2014 editions of The Legal 500 UK for venture capital and mergers and acquisitions: mid market, with sources stating that he is "superb," "very responsive" and "well regarded for [his] advice."

Insights & News

Credentials

  • Education

    • MA, University of Cambridge

  • Admissions

    • England and Wales, Solicitor

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.